CIF Chile

What CIF Chile does

CIF Chile (Cámara de la Innovación Farmacéutica) is a private non-profit industry chamber founded in 1953 and headquartered in Santiago, Chile, that represents multinational innovative pharmaceutical laboratories operating in the country, including Roche, Pfizer, Novartis, MSD, AstraZeneca, BMS, Sanofi, Takeda, AbbVie, J&J, Boehringer Ingelheim, and others. Its core function is collective advocacy and ecosystem articulation: it serves as the unified interlocutor between the innovative pharma industry and Chilean government bodies (MINSAL, SUBREI, ISP, Subsecretaría de Ciencia), multilateral organizations (CEPAL, FIFARMA), and academic institutions (Universidad Católica), on regulatory efficiency, market access, IP frameworks, and clinical research competitiveness.

CIF Chile operates a small portfolio of digital platforms and programs rather than a unified software product. Its technology surface includes estudiosclinicos.cl (a public clinical trial search platform), the Plataforma de Transparencia (an open-data repository registering value transfers between member labs and healthcare professionals or patient organizations), the Unidad Transparenta self-regulatory unit, the Ruta del Paciente patient-navigation resource, and the corporate website hosting studies and the Premio Innovadoras en Salud award program. These are primarily informational and compliance tools; no proprietary AI or advanced analytics capabilities are disclosed. Its recurring knowledge products include the FIFARMA W.A.I.T Indicator, the Caracterización del Gasto Público en Medicamentos study (with Escuela de Gobierno UC), and policy proposals such as 'Salud + Innovación: 15 medidas al 2030'.

The organization's revenue model is membership dues paid by associated pharmaceutical laboratories, supplemented by event sponsorships (e.g., from AstraZeneca, Boehringer Ingelheim, Ferrer, Merck, MSD for Premio Innovadoras en Salud). Revenue is not publicly disclosed. Operationally, CIF Chile runs on a lean team of 13 employees, supplemented by a volunteer board of directors composed of country-level general managers from member companies, with Pierina Rossetti (Ferrer) as President and Mariela Formas as Executive Vice President.

Name

CIF Chile

Legal name

Cámara de la Innovación Farmacéutica

Website

https://cifchile.cl

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

CIF Chile is a Santiago-based non-profit chamber founded in 1953 that represents multinational innovative pharmaceutical laboratories in Chile, providing collective advocacy, policy research, transparency platforms, and clinical research positioning to its ~16-18 member companies including Roche, Pfizer, Novartis, and AstraZeneca.

Ownership category

akta.pro rank

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels1 record

Marketing channels6 records

Core offering

CIF Chile is a non-profit pharmaceutical industry chamber that represents innovative pharmaceutical companies operating in Chile. It provides industry advocacy and policy development, operates digital platforms for clinical trial information (estudiosclinicos.cl) and transparency reporting on value transfers, runs self-regulation programs including the Código de Buenas Prácticas, and organizes industry events including the Premio Innovadoras en Salud awards program.

Product overview

CIF Chile (Cámara de la Innovación Farmacéutica) is a pharmaceutical industry chamber that operates a portfolio of digital platforms and programs rather than a unified software product. Its core offerings include the Estudios Clínicos platform for clinical trial information, the Plataforma de Transparencia for compliance reporting, the Premio Innovadoras en Salud awards program, and published studies on healthcare policy. These services function as interconnected resources for the pharmaceutical ecosystem rather than an integrated product suite.

Differentiator

Problem solved

Functional benefit

Products and services

• Plataforma de Estudios Clínicos A public platform providing information about clinical trials being conducted in Chile, allowing patients and the public to search for studies on different diseases and identify participating centers and clinics.
• Plataforma de Transparencia An open data repository that registers interactions made by member laboratories with healthcare professionals and patient organizations, documenting 'value transfers' involving payments or monetary support to strengthen industry transparency.
• Ruta del Paciente A resource providing information and guidance to help patients navigate the Chilean healthcare system and access available services.
• Estudios y Publicaciones Published studies including 'Salud + Innovación: 15 medidas para transformar el bienestar del país al 2030', 'Caracterización del Gasto Público en Medicamentos', reports on Health Technology Assessment (ETESA), risk-sharing agreements, and the FIFARMA W.A.I.T Indicator analyzing access to innovative medicines.
• Premio Innovadoras en Salud An annual recognition award program honoring women who transform healthcare in Chile through science, research, management, and public policy, with categories for Compromiso Público, Investigación, Ejecutivas, Regulatorio e Integridad, and Empresas.

Quantifiable outcome

• US$122 million in clinical research investment mobilized in 2021
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core, tactical and strategic.

• Mujeres EmpresariascoreStrategic or Co-development Partner · 13 July 2026Joint organizers of the Premio Innovadoras en Salud award program, recognizing women who transform healthcare in Chile. This partnership has generated over 2,000 nominations across two editions.
• La TerceratacticalGTM or Marketing Partner · 13 July 2026Media partner for the Innovadoras en Salud award program, providing coverage and visibility for award winners and nominees.
• AstraZeneca, Boehringer Ingelheim, Ferrer, Merck, MSDtacticalGTM or Marketing Partner · 13 July 2026Sponsors of the 2026 Innovadoras en Salud award edition, providing support for the recognition program for women in healthcare.
• CEPAL (UN Economic Commission for Latin America)coreStrategic or Co-development Partner · 14 May 2026Co-organized the 2026 Clinical Trials Seminar 'Ensayos Clínicos: Oportunidades para Chile en Salud, Innovación y Desarrollo Productivo' held at CEPAL's Santiago headquarters, bringing together over 200 participants from government, academia, and industry.
• CORFO (Transforma Innovación en Salud)coreStrategic or Co-development Partner · 14 May 2026Co-organized the 2026 Clinical Trials Seminar alongside CEPAL and CORFO's Transforma Innovación en Salud program, focused on positioning Chile as a regional clinical research hub.
• IQVIAstrategicStrategic or Co-development Partner · 14 May 2026Provided analytical backing for the 2026 Clinical Trials Seminar. IQVIA is a global leader in healthcare market intelligence, contributing data and expertise on clinical trial trends and Chile's competitive position.
• FIFARMAstrategicStrategic or Co-development Partner · 28 April 2026Co-organized the 'PI en Acción: Estándares Globales como Motor de Inversión' seminar on intellectual property as a driver of economic development and investment attraction.
• Escuela de Gobierno UCstrategicStrategic or Co-development Partner · 1 January 2025Academic partner for the 'Caracterización del Gasto Público en Medicamentos 2025' study on public pharmaceutical spending, developed with researchers Pablo Celhay, Benjamin Ahumada, and Francisco León.
• FIFARMAstrategicStrategic or Co-development Partner · 1 January 2025Partner in publishing the FIFARMA W.A.I.T Indicator 2025, analyzing access times to innovative medicines in Latin America.
• Universidad Católica de Chile (Faculty of Law)strategicStrategic or Co-development Partner · 1 January 2024Partner in the Sistema de Autorregulación de Buenas Prácticas Gremiales UC, providing independent oversight and dispute resolution for ethical standards in the pharmaceutical industry.
• Chile TransparentetacticalStrategic or Co-development PartnerIndependent transparency organization that verified CIF Chile's website content structure based on Transparency International's reporting model.
• Gobierno de Chile (MINSAL)coreStrategic or Co-development PartnerActive dialogue and collaboration with the Ministry of Health, including meetings with Minister May Chomali in April 2026 to discuss healthcare system strengthening and innovation.
• Subsecretaría de Relaciones Económicas Internacionales (SUBREI)coreStrategic or Co-development PartnerGovernment partner for IP policy dialogue, with Under-Secretary Paula Estévez participating in seminars on property rights and innovation investment.
• Subsecretaría de Ciencia, Tecnología, Conocimiento e InnovacióncoreStrategic or Co-development PartnerGovernment partner for innovation policy discussions, with Under-Secretary Rafael Araos emphasizing the role of the State in designing modern regulatory frameworks.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Regional players

• CANIFARMA (Cámara Nacional de la Industria Farmacéutica): Mexico's national pharmaceutical industry chamber. Comparable as a national industry association with policy, regulatory and ethics functions, operating in a different LatAm market with overlapping but not directly competing scope.
• JPMA (Japan Pharmaceutical Manufacturers Association): Japanese innovative pharma manufacturers association. Functionally comparable on IP advocacy, transparency and international dialogue, in a different geography with much larger member base.
• Interfarma (Associação da Indústria Farmacêutica de Pesquisa): Brazil's innovative pharma research association. Directly comparable in scope (advocacy, transparency, clinical research promotion), but operates in a much larger domestic market and a different geographic footprint.
• ALIFAR (Asociación Latinoamericana de Industrias Farmacéuticas): Latin American association of national pharmaceutical manufacturers. Thematically comparable as a regional industry body, though oriented more to generics/production than the innovative-pharma focus of CIF Chile.
• ABPI (Association of the British Pharmaceutical Industry): U.K. trade association for research-based pharma companies. Comparable in advocacy, ABPI Code of Practice self-regulation and clinical research positioning, though operating in a different regulatory environment.
• Farmaindustria (Asociación Nacional Empresarial de la Industria Farmacéutica): Spanish innovative pharma industry association. Closely comparable transparency platform (Sistema de Transparencia) and self-regulation system, useful as a benchmark for CIF Chile's Plataforma de Transparencia and Unidad Transparenta.

Broad incumbents

• EFPIA (European Federation of Pharmaceutical Industries and Associations): European peak body for the innovative pharmaceutical industry. Comparable in advocacy, transparency disclosure platform (EFPIA Disclosure Code) and clinical research positioning work; relevant regional peer for benchmarking CIF Chile's ethics infrastructure.
• PhRMA (Pharmaceutical Research and Manufacturers of America): U.S. innovative pharma trade association representing research-based biopharmaceutical companies. Highly comparable advocacy and transparency functions (PhRMA Code, member value-transfer disclosures) at a much larger scale.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): Global federation of pharma industry associations and companies. Operates the global BioEquivalence and ethics codes; serves as CIF Chile's ultimate umbrella peer for international advocacy and standards alignment.

Direct peers

• FIFARMA (Federación Latinoamericana de la Industria Farmacéutica): Latin American federation of innovative pharmaceutical industry chambers, of which CIF Chile is a national member. Directly comparable as the regional peak body that aggregates country chambers, runs the W.A.I.T. Indicator, and lobbies on IP, regulatory and access policy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cifchile

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIF Chile